Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
Targeted therapy with tyrosine kinase inhibitors (TKIs) was the standard of care for metastatic renal cell carcinoma (mRCC) until recently, when new first-line combinations with immuno-oncology (IO) agents were approved. We evaluated IO uptake in both first-line and later-line treatment in routine c...
Saved in:
Main Authors: | Hilin Yildirim, Anke Richters, Adriaan D. Bins, Arnoud W. Postema, Maureen J.B. Aarts, Martijn G.H. van Oijen, Patricia J. Zondervan, Katja K.H. Aben |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | European Urology Open Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168325000503 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study
by: Chenming Liu, et al.
Published: (2025-02-01) -
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01) -
Molecular mechanisms of renal cell carcinoma metastasis and potential targets for therapy
by: Xinwei Li, et al.
Published: (2025-01-01) -
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by: Ilya Tsimafeyeu, et al.
Published: (2024-12-01) -
The prognostic utility of the ratio of lymphocyte to monocyte in patients with metastatic colorectal cancer: a systematic review and meta-analysis
by: Pingping Mei, et al.
Published: (2025-02-01)